Abstract:Abstract Zika virus (ZIKV) is an arbovirus from the Flaviviridae family and Flavivirus genus. Neurological events have been associated with ZIKV-infected individuals, such as Guillain-Barré syndrome, an autoimmune acute neuropathy that causes nerve demyelination and can induce paralysis. With the increase of ZIKV infection incidence in 2015, malformation and microcephaly cases in newborns have grown considerably, which suggested congenital transmission. Therefore, the development of an effective vaccine against ZIKV became an urgent need. Live attenuated vaccines present some theoretical risks for administration in pregnant women. Thus, we developed an in silico multiepitope vaccine against ZIKV. All structural and non-structural proteins were investigated using immunoinformatics tools designed for the prediction of CD4 + and CD8 + T cell epitopes. We selected 13 CD8 + and 12 CD4 + T cell epitopes considering parameters such as binding affinity to HLA class I and II molecules, promiscuity based on the number of different HLA alleles that bind to the epitopes, and immunogenicity. ZIKV Envelope protein domain III (EDIII) was added to the vaccine construct, creating a hybrid protein domain-multiepitope vaccine. Three high scoring continuous and two discontinuous B cell epitopes were found in EDIII. Aiming to increase the candidate vaccine antigenicity even further, we tested secondary and tertiary structures and physicochemical parameters of the vaccine conjugated to four different protein adjuvants: flagellin, 50S ribosomal protein L7/L12, heparin-binding hemagglutinin, or RS09 synthetic peptide. The addition of the flagellin adjuvant increased the vaccine's predicted antigenicity. In silico predictions revealed that the protein is a probable antigen, non-allergenic and predicted to be stable. The vaccine’s average population coverage is estimated to be 87.86%, which indicates it can be administered worldwide. Peripheral Blood Mononuclear Cells (PBMC) of individuals with previous ZIKV infection were tested for cytokine production in response to the pool of CD4 and CD8 ZIKV peptide selected. CD4 + and CD8 + T cells showed significant production of IFN-γ upon stimulation and IL-2 production was also detected by CD8 + T cells, which indicated the potential of our peptides to be recognized by specific T cells and induce immune response. In conclusion, we developed an in silico universal vaccine predicted to induce broad and high-coverage cellular and humoral immune responses against ZIKV, which can be a good candidate for posterior in vivo validation.

Nystatin Production by a Local Streptmyces sp. Isolated from Egyptian Soil

Identification of Protective CD8 T Cell Responses in a Mouse Model of Zika Virus Infection

Amberlyst A-27, an Efficient Heterogeneous Catalyst for the Michael Reaction of Nitroalkanes with beta-Substituted Alkene Acceptors.

Delineating Antibody Recognition Against Zika Virus During Natural Infection.

Characterization of Two Highly Specific Monoclonal Antibodies Targeting the Glycan Loop of the Zika Virus Envelope Protein

Comprehensive analysis of early T cell responses to acute Zika Virus infection during the first epidemic in Bahia, Brazil

Molecular Determinants of Human Neutralizing Antibodies Isolated from a Patient Infected with Zika Virus.

In silico construction of a multiepitope Zika virus vaccine using immunoinformatics tools

Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated Vaccine

Analysis of Memory Antibody Responses in Individuals with Zika-Associated Guillain–Barré Syndrome

Mechanisms for excited state relaxation and dissociation of oxymyoglobin and carboxymyoglobin.

Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes

Single-cell analysis reveals an antiviral network that controls Zika virus infection in human dendritic cells

Single cell analysis reveals an antiviral network that controls Zika virus infection in human dendritic cells

Neutralization of Zika Virus by Germline-Like Human Monoclonal Antibodies Targeting Cryptic Epitopes on Envelope Domain III

NK Cell Responses in Zika Virus Infection Are Biased towards Cytokine-Mediated Effector Functions

An immunoinformatics and structural vaccinology approach to design a novel and potent multi-epitope base vaccine targeting Zika virus

Hide and Seek: The Interplay Between Zika Virus and the Host Immune Response

Characterization of CD8 + T cells in immune-privileged organs of ZIKV-infected Ifnar1 −/− mice

Burst level resources allocation on the up/down link in a low Earth orbit satellite constellation

Development of a Potent and Protective Germline-Like Antibody Lineage Against Zika Virus in a Convalescent Human